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Abstract: Stenotrophomonas maltophilia is an emerging global opportunistic pathogen, responsible for a
wide range of human infections, including respiratory tract infections. Intrinsic multidrug resistance
and propensity to form biofilms make S. maltophilia infections recalcitrant to treatment. Colistin is
among the second-line options in case of difficult-to-treat S. maltophilia infections, with the advantage
of being also administrable by nebulization. We investigated the potential synergism of colistin in
combination with N-acetylcysteine (NAC) (a mucolytic agent with antioxidant and anti-inflammatory
properties) against S. maltophilia grown in planktonic phase and biofilm. Eighteen S. maltophilia clinical
isolates (comprising three isolates from cystic fibrosis (CF) and two trimethoprim-sulfamethoxazole
(SXT)-resistant strains) were included. Checkerboard assays showed a synergism of colistin/NAC
combinations against the strains with colistin Minimum Inhibitory Concentration (MIC) >2 µg/mL
(n = 13), suggesting that NAC could antagonize the mechanisms involved in colistin resistance.
Nonetheless, time–kill assays revealed that NAC might potentiate colistin activity also in case of
lower colistin MICs. A dose-dependent potentiation of colistin activity by NAC was also clearly
observed against S. maltophilia biofilms, also at sub-MIC concentrations. Colistin/NAC combinations,
at concentrations likely achievable by topical administration, might represent a valid option for the
treatment of S. maltophilia respiratory infections and should be examined further.
Keywords: colistin; N-acetylcysteine; Stenotrophomonas maltophilia; biofilm
1. Introduction
Stenotrophomonas maltophilia is an emerging global opportunistic pathogen, responsible for a
wide range of human infections, including chronic lung colonization and acute exacerbations in
patients affected by chronic respiratory diseases, such as cystic fibrosis (CF), chronic obstructive
pulmonary disease (COPD), and bronchiectasis [1]. As reported by the Italian Cystic Fibrosis Registry,
S. maltophilia is the second most common non-fermenting Gram-negative respiratory pathogen,
following Pseudomonas aeruginosa, in patients affected by CF, with a prevalence of chronic lung
colonization of 4.6% and 4.7% in adult and pediatric patients, respectively [2]. Despite the precise
clinical relevance of S. maltophilia in CF remains undetermined [3,4], chronic pulmonary colonization
by S. maltophilia has been recently associated with an increased risk of pulmonary exacerbations
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requiring intravenous antibiotics, lung transplantation, and death [5–7]. Due to intrinsic and acquired
multidrug resistance mechanisms and the propensity to grow as biofilm, S. maltophilia infections are
difficult-to-treat and the therapeutic options are very limited [1,5,8–11]. Clinical breakpoints for the
interpretation of susceptibility testing are available only for trimethoprim-sulfamethoxazole (SXT) (i.e.,
the first-line treatment option) and few other compounds, namely levofloxacin, some beta-lactams (i.e.,
ticarcillin-clavulanate and ceftazidime), minocycline, and chloramphenicol [12,13].
In order to find new drugs and their combinations to improve outcomes of difficult-to-treat
respiratory tract infections, a renewed interest has been recently focused on topical routes of
administration (e.g., inhalation, nebulization, and aerosolization), which allow the achievement
of high drug concentrations in the lungs with limited systemic toxicity [14,15].
N-acetylcysteine (NAC) is a mucolytic agent commonly administered together with antibiotics
for the management of lower respiratory tract infections, especially in patients with chronic
respiratory diseases characterized by abundant and/or thick mucus production (i.e., CF, COPD,
and bronchiectasis) [16]. In addition, an increasing amount of data points to an intrinsic antimicrobial
and antibiofilm activity of NAC against some pathogens, including relevant CF pathogens such as
P. aeruginosa, S. maltophilia, and Burkholderia cepacia complex (BCC) [16,17]. Colistin is among the
last-resort agents for the treatment of infections caused by multidrug-resistant Gram-negative bacteria,
and inhaled colistin (alone or in combination with intravenous colistin) has been increasingly used for
the treatment of difficult-to-treat respiratory tract infections, especially in CF [15,18–20]. Nonetheless,
apart from intrinsic resistance of BCC, colistin is not recommended as first-line treatment option
for other relevant CF pathogens (e.g., S. maltophilia and Achromobacter xylosoxidans), due to lack of
clinical breakpoints and high rates of organisms with high Minimum Inhibitory Concentration (MIC)
values [21]. Recently, it has been shown that colistin/NAC combinations exert a relevant antimicrobial
and antibiofilm synergistic activity against Acinetobacter baumannii [22]. In particular, high NAC
concentrations (potentially achievable by topical administration) can revert the colistin resistance
phenotype in this pathogen [22].
The aim of this study was to investigate the potential synergism of colistin in combination with
NAC against S. maltophilia strains grown in planktonic phase and in vitro biofilm models, at drugs
concentrations likely achievable by topical administration.
2. Results
2.1. Colistin Susceptibility of S. maltophilia Strains Included in the Study
The study was performed with 18 S. maltophilia clinical isolates (including isolates from CF and
SXT-resistant strains), which had been previously investigated for NAC susceptibility [17]. Among the
strains tested, 13 showed colistin MIC >2 µg/mL (MIC range 4–>256 µg/mL), and for the purposes of
this study were categorized as “colistin-resistant” (according to the colistin clinical breakpoints for
P. aeruginosa) (Table 1) [12,13]. The remaining 5 isolates showed colistin MIC <2 µg/mL (MIC range
0.125–1 µg/mL) and were therefore categorized as “colistin-susceptible” (Table 1). Overall, colistin
susceptibility patterns of strains included in this study were consistent with those recently reported in
other studies on S. maltophilia antibiotic susceptibility [8,23].
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Table 1. Main features of the 18 S. maltophilia clinical isolates investigated in this study.
Strain MLST Origin
Antibiotics
MIC (µg/mL)
COL SXT CAZ LVX MIN
Z63 NA BSI >256 0.5 2 ≤0.25 0.125
Z64 NA BSI 64 2 64 2 2
Z119 NA LRTI 32 0.5 32 2 0.5
Z128 NA LRTI 32 ≤0.25 4 1 0.25
Z117 NA LRTI 16 0.5 64 0.5 0.25
Z129 NA LRTI 16 ≤0.25 4 1 0.25
Z65 NA IAI 8 1 64 2 1
Z118 ST162 LRTI 8 0.5 8 2 0.25
Z130 NA IAI 8 0.5 16 16 2
Z131 NA BSI 8 >8 64 32 1
Z132 NA LRTI 8 1 2 16 1
Z157 NA CF 8 0.5 4 2 1
Z155 ST335 CF 4 >8 32 4 2
Z116 NA LRTI 1 0.5 16 2 0.25
Z156 NA CF 0.25 1 16 2 0.25
Z120 ST334 LRTI 0.25 0.5 32 1 0.5
Z66 NA LRTI 0.25 0.5 ≤1 1 0.25
Z133 NA LRTI 0.125 1 2 1 0.25
MLST, multi locus sequence type; NA, not available; BSI, bloodstream infection; LRTI, lower respiratory tract
infection; IAI, intra-abdominal infection; CF, cystic fibrosis; COL, colistin (breakpoint not available); SXT,
trimethoprim-sulfamethoxazole (S ≤2/38, R ≥4/76 µg/mL); CAZ, ceftazidime (S ≤8, I = 16, R ≥16 µg/mL); LVX,
levofloxacin (S ≤2, I = 4, R ≥8 µg/mL); MIN, minocycline (S ≤4, I = 8, R ≥16 µg/mL). S, susceptible; I, intermediate;
R, resistant [13].
2.2. In Vitro Synergism of Colistin/NAC Combinations against S. maltophilia Strains Grown in
Planktonic Phase
Checkerboard assays showed a notable synergistic activity of colistin/NAC combinations against
the 13 colistin-resistant strains (i.e., fractional inhibitory concentration index (FICI) ≤0.5) (Table 2).
In particular, a decrease of colistin MICs to ≤2 µg/mL (i.e., the susceptibility breakpoint for P. aeruginosa)
was observed with 12 strains in the presence of NAC 4 mg/mL and with all strains in the presence of
NAC >4 mg/mL (Table 2). The 5 colistin-susceptible strains showed no synergistic effect, although a
trend toward colistin MIC decrease was observed in the presence of increasing NAC concentrations
(Table 2).
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Table 2. Colistin MICs (µg/mL) and corresponding fractional inhibitory concentration indices (FICIs) in the presence of increasing N-acetylcysteine (NAC)
concentrations for the 18 S. maltophilia clinical isolates investigated in this study. MIC and FICI values corresponding to synergism are shown with grey shading.
Strain
MIC NAC Concentrations (mg/mL)
NAC
(mg/mL)
COL
(µg/mL)
0.5 1 2 4 8 16 32
COL
(µg/mL) FICI
COL
(µg/mL) FICI
COL
(µg/mL) FICI
COL
(µg/mL) FICI
COL
(µg/mL) FICI
COL
(µg/mL) FICI
COL
(µg/mL) FICI
1-17
Z63 32 >256 32 0.14 16 0.09 2 0.07 1 0.13 0.5 0.25 ≤0.25 0.50 ≤0.25 1.00
Z64 32 64 64 0.02 32 0.53 16 0.31 1 0.14 1 0.27 0.5 0.51 0.25 1.00
Z119 32 32 32 1.02 16 0.53 8 0.31 4 0.25 1 0.28 1 0.53 ≤0.25 1.01
Z128 16 32 32 1.03 32 1.06 16 0.63 2 0.31 1 0.53 ≤0.25 1.01 ≤0.25 2.01
Z117 32 16 32 2.02 32 2.03 16 1.06 1 0.19 1 0.31 ≤0.25 0.52 ≤0.25 1.02
Z129 32 16 32 2.02 16 1.03 16 1.06 2 0.25 1 0.31 0.5 0.53 ≤0.25 1.02
Z65 32 8 16 2.02 8 1.03 4 0.56 1 0.25 ≤0.25 0.28 ≤0.25 0.53 ≤0.25 1.03
Z118 16 8 2 0.28 2 0.31 2 0.38 1 0.38 ≤0.25 0.53 ≤0.25 1.03 ≤0.25 2.03
Z130 32 8 16 2.02 8 1.03 2 0.31 1 0.25 1 0.38 0.5 0.56 ≤0.25 1.03
Z131 32 8 16 2.02 8 1.03 4 0.56 2 0.38 1 0.38 0.5 0.56 ≤0.25 1.03
Z132 32 8 16 2.02 8 1.03 2 0.31 1 0.25 1 0.38 0.5 0.56 ≤0.25 1.03
Z157 32 8 32 4.02 32 4.03 8 1.06 2 0.38 1 0.38 1 0.63 ≤0.25 1.03
Z155 16 4 4 1.03 4 1.06 2 0.63 1 0.50 1 0.75 ≤0.25 1.06 ≤0.25 2.06
Z116 32 1 1 1.02 1 1.03 1 1.06 1 1.13 0.5 0.75 0.25 0.75 ≤0.003 1.00
Z156 16 0.25 0.5 2.03 0.5 2.06 0.25 1.13 0.25 1.25 0.06 0.75 ≤0.003 1.02 ≤0.003 2.02
Z120 16 0.25 0.5 2.03 0.5 2.06 0.25 1.13 0.25 1.25 0.06 0.75 ≤0.003 1.02 ≤0.003 2.02
Z66 16 0.25 0.25 1.03 0.25 1.06 0.25 1.13 0.125 0.75 0.125 1.00 ≤0.003 1.02 ≤0.003 2.02
Z133 32 0.125 0.25 2.03 0.25 2.06 0.125 1.13 0.125 1.25 0.125 1.50 ≤0.003 1.03 ≤0.003 2.03
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2.3. Time-Kill Assays of Colistin/NAC Combinations against Three Selected S. Maltophilia Strains Grown in
Planktonic Phase
Time–kill assays were performed with three selected S. maltophilia strains, namely Z131 (from
bloodstream infection; resistant to SXT, ceftazidime and levofloxacin; colistin MIC = 8 µg/mL), Z157
(from CF; colistin MIC = 8 µg/mL), and Z66 (from lower respiratory tract infection; colistin MIC =
0.25 µg/mL). Colistin and NAC concentrations potentially achievable by topical administration were
tested. Results showed a relevant dose-dependent potentiation of colistin activity by NAC, with the
three strains investigated (Figure 1a,b). Overall, these data were in accordance with those obtained
in checkerboard assays, supporting the notion of synergism of colistin/NAC combinations, and of a
possible role of NAC in reverting colistin resistance in S. maltophilia.
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2.4. In Vitro Activity of Colistin/NAC Combinations against S. maltophilia Biofilms
The antibiofilm activity of colistin/NAC combinations was tested against all the 18 S. maltophilia
strains, using a standardized in vitro biofilm model [24]. Preformed S. maltophilia biofilms were
exposed to nine different colistin/NAC combinations, and the antibiofilm activity was evaluated by
determining the number of viable cells in biofilms treated with colistin/NAC combinations compared
to colistin alone. Colistin and NAC concentrations potentially achievable by topical administration
were tested. In the in vitro biofilm model adopted, S. maltophilia biofilms ranged from 2.5 ± 1.7 ×
105 to 1.3 ± 0.4 × 107 colony-forming units (CFU)/peg after 24 h of growth. Overall, a synergism of
colistin/NAC combinations was observed with all the colistin-resistant strains, except for strain Z155
(colistin MIC = 4 µg/mL) (Figures 2–4). In particular, the combination colistin 8 µg/mL plus NAC
16 mg/mL was synergistic against the majority of colistin-resistant strains (i.e., 7 out of 13 strains)
(Figures 2–4). S. maltophilia Z155 (the only colistin-resistant strain with which no synergism was
observed) was extremely susceptible to NAC 16 mg/mL, which alone achieved complete eradication of
the in vitro biofilm model (Figure 4). In addition, with two strains (i.e., Z119 and Z131), a paradoxical
effect of the combination colistin 128 µg/mL plus NAC 1.6 mg/mL was observed, which will deserve
further attention (Figures 2 and 3).
A statistically significant potentiation of colistin activity by NAC was also observed with one of
the five colistin-susceptible strains (i.e., Z156) (Figure 4). For the remaining four colistin-susceptible
strains, a trend suggesting a potentiation of colistin activity by NAC was observed, even though the
results did not reach a statistical significance, likely due to not optimal colistin concentrations tested.
In order to partially address this point, strain Z133 was selected and tested also with a lower range of
colistin concentrations. Results showed a clear synergism of colistin/NAC combinations also against
this strain (Figure 5).
Taken together, these results indicated a NAC-mediated dose-dependent potentiation of the
antibiofilm activity of colistin against S. maltophilia strains. Biofilm susceptibility to colistin/NAC
combinations was anyway strain-dependent and not directly correlated to colistin or NAC MICs.
Antibiotics 2019, 20, x FOR PEER REVIEW 6 of 13 
2.4. In Vitro Activity of Colistin/NAC Combinations against S. maltophilia Biofilms 
The antibiofilm activity of colistin/NAC combinations was tested against all the 18 S. maltophilia 
strains, using a standardized in vitro biofilm model [24]. Preformed S. maltophilia biofilms were 
exposed to nine different colistin/NAC combinations, and the antibiofilm activity was evaluated by 
determining the number of viable cells in biofilms treated with colistin/NAC combinations compared 
to colistin alone. Colistin and NAC concentrations potentially achievable by topical administration 
were tested. In the in vitro biofilm model adopted, S. maltophilia biofilms ranged from 2.5 ± 1.7 × 105 
to 1.3 ± 0.4 × 107 colony-forming units (CFU)/peg after 24 hours of growth. Overall, a synergism of 
colistin/NAC combinations was observed with all the colistin-resistant strains, except for strain Z155 
(colistin IC = 4 µg/mL) (Figures 2–4). In particular, the combination colistin 8 µg/mL plus NAC 16 
mg/mL was synergistic against the majority of colistin-resistant strains (i.e., 7 out of 13 strains) 
(Figures 2–4). S. maltophilia Z155 (the only colistin-resistant strain with which no synergism was 
observed) was extremely susceptible to NAC 16 mg/mL, which alone achieved complete eradication 
of the in vitro biofilm model (Figure 4). In addition, with two strains (i.e., Z119 and Z131), a 
paradoxical effect of the combination colistin 128 µg/mL plus NAC 1.6 mg/mL was observed, which 
will deserve further attention (Figures 2,3). 
A statistically significant potentiation of colistin activity by NAC was also observed with one of 
the five colistin-susceptible strains (i.e., Z156) (Figure 4). For the remaining four colistin-susceptible 
strains, a trend suggesting a potentiation of colistin activity by NAC was observed, even though the 
results did not reach a statistical significance, likely due to not optimal colistin concentrations tested. 
In order to partially address this point, strain Z133 was selected and tested also with a lower range 
of colistin concentrations. Results showed a clear synergism of colistin/NAC combinations also 
against this strain (Figure 5). 
Taken together, these results indicated a NAC-mediated dose-dependent potentiation of the 
antibiofil  activity of colistin against S. maltophilia strains. Biofil  susceptibility to colistin/NAC 
co binations was anyway strain-dependent and not directly correlated to colistin or NAC MICs. 
 
 
 
 
Figure 2. Cont.
Antibiotics 2019, 8, 101 7 of 13
Antibiotics 2019, 20, x FOR PEER REVIEW 7 of 13 
 
Figure 2. Antibiofilm activity of colistin/NAC combinations against S. maltophilia strains with colistin 
MIC range 16–>256 µg/mL. The x-axis is set at the limit of detection (20 CFU/peg). CFU: Colony-
forming units. Each data point represents a replicate, for a total of 12 replicates per condition. 
 
Figure 3. Antibiofilm activity of colistin/NAC combinations against S. maltophilia strains with colistin 
MIC = 8 µg/mL. The x-axis is set at the limit of detection (20 CFU/peg). CFU: Colony-forming units. 
Each data point represents a replicate, for a total of 12 replicates per condition. 
 
Control
NAC 1.6 mg/ml
NAC 8 mg/ml
NAC 16 mg/ml
COL 8 g/ml
COL 8 g/ml + NAC 1.6 mg/ml
COL 8 g/ml + NAC 8 mg/ml
COL 8 /ml + NAC 16 mg/ml
COL 32 g/ml
COL 32 g/ml + NAC 1.6 mg/ml
COL 32 g/ml + NAC 8 mg/ml
COL 32 g/ml + NAC 16 mg/ml
COL 128 g/ml
COL 128 g/ml + NAC 1.6 mg/ml
COL 128 g/ml + NAC 8 mg/ml
COL 128 g/ml + NAC 16 mg/ml
  
  
  
Control
NAC 1.6 mg/ml
NAC 8 mg/ml
NAC 16 mg/ml
COL 8 g/ml
COL 8 g/ml + NAC 1.6 mg/ml
COL 8 g/ml + NAC 8 mg/ml
COL 8 /ml + NAC 16 mg/ml
COL 32 g/ml
COL 32 g/ml + NAC 1.6 mg/ml
COL 32 g/ml + NAC 8 mg/ml
COL 32 g/ml + NAC 16 mg/ml
COL 128 g/ml
COL 128 g/ml + NAC 1.6 mg/ml
COL 128 g/ml + NAC 8 mg/ml
COL 128 g/ml + NAC 16 mg/ml
Figure 2. Antibiofilm activity of colistin/NAC combinations against S. maltophilia strains with colistin
MIC range 16–>256 µg/mL. The x-axis is set at the limit of detection (20 CFU/peg). CFU: Colony-forming
units. Each data point represents a replicate, for a total of 12 replicates per condition.
tibiotics 2019, 20, x FOR PEER REVIEW 7   
 
Figure 2. Antibiofilm activity of colistin/NAC combinations against S. maltophilia strains with colistin 
MIC range 16–>256 µg/mL. The x-axis is set at the limit of detec ion (20 CFU/peg). CFU: C ony-
forming units. Each data point represent  a replicat , for a total of 12 replicates per condition. 
 
Figure 3. Antibiofilm activity of colistin/NAC combinations against S. maltophilia strains with colistin 
MIC = 8 µg/mL. The x-axis is set at the limit of detection (20 CFU/peg). CFU: Colony-forming units.
Each data point represents a replica e, for a otal of 12 replicates per condition. 
 
Control
NAC 1.6 mg/ml
NAC 8 mg/ml
NAC 16 mg/ml
COL 8 g/ml
COL 8 g/ml + NAC 1.6 mg/ml
COL 8 g/ml + NAC 8 mg/ml
COL 8 /ml + NAC 16 mg/ml
COL 32 g/ml
COL 32 g/ml + NAC 1.6 mg/ml
COL 32 g/ml + NAC 8 mg/ml
COL 32 g/ml + NAC 16 mg/ml
COL 128 g/ml
COL 128 g/ml + NAC 1.6 mg/ml
COL 128 g/ml + NAC 8 mg/ml
COL 128 g/ml + NAC 16 mg/ml
  
  
  
Control
NAC 1.6 mg/ml
NAC 8 mg/ml
NAC 16 mg/ml
COL 8 g/ml
COL 8 g/ml + NAC 1.6 mg/ml
COL 8 g/ml + NAC 8 mg/ml
COL 8 /ml + NAC 16 mg/ml
COL 32 g/ml
COL 32 g/ml + NAC 1.6 mg/ml
COL 32 g/ml + NAC 8 mg/ml
COL 32 g/ml + NAC 16 mg/ml
COL 128 g/ml
COL 128 g/ml + NAC 1.6 mg/ml
COL 128 g/ml + NAC 8 mg/ml
COL 128 g/ml + NAC 16 mg/ml
Figure 3. Antibiofilm activity of colistin/NAC combinations against S. maltophilia strains with colistin
MIC = 8 µg/mL. The x-axis is set at the limit of detection (20 CFU/peg). CFU: Colony-forming units.
Each data point represents a replicate, for a total of 12 replicates per condition.
Antibiotics 2019, 8, 101 8 of 13Antibiotics 2019, 20, x FOR PEER REVIEW 8 of 13 
 
Figure 4. Antibiofilm activity of colistin/NAC combinations against S. maltophilia strains with colistin 
MIC 0.125–4 µg/mL. The x-axis is set at the limit of detection (20 CFU/peg). CFU: Colony-forming 
units. Each data point represents a replicate, for a total of 12 replicates per condition. 
 
Figure 5. Antibiofilm activity of colistin/NAC combinations against S. maltophilia Z133. The x-axis is 
set at the limit of detection (20 CFU/peg). CFU: Colony-forming units. Each data point represents a 
replicate, for a total of 12 replicates per condition. 
  
  
  
 
Control
NAC 1.6 mg/ml
NAC 8 mg/ml
NAC 16 mg/ml
COL 8 g/ml
COL 8 g/ml + NAC 1.6 mg/ml
COL 8 g/ml + NAC 8 mg/ml
COL 8 /ml + NAC 16 mg/ml
COL 32 g/ml
COL 32 g/ml + NAC 1.6 mg/ml
COL 32 g/ml + NAC 8 mg/ml
COL 32 g/ml + NAC 16 mg/ml
COL 128 g/ml
COL 128 g/ml + NAC 1.6 mg/ml
COL 128 g/ml + NAC 8 mg/ml
COL 128 g/ml + NAC 16 mg/ml
 
Figure 4. Antibiofilm activity of colistin/NAC combinations against S. maltophilia strains with colistin
MIC 0.125–4 µg/mL. The x-axis is set at the limit f detecti (20 CFU/peg). CFU: Colony-forming units.
Each data point represents a replicat , for a total of 12 r plicates per condition.
Antibiotics 2019, 20, x FOR PEER REVIEW 8 of 13 
 
Figure 4. ntibiofil  activity of colistin/  co binations against S. altophilia strains ith colistin 
IC 0.125–4 µg/mL. The x-axis is set at the limit of detection (20 CFU/peg). CFU: Colony-forming 
units. Each data point represents a replicate, for a total of 12 replicates per condition. 
 
Figure 5. Antibiofilm activity of colistin/NAC combinations against S. maltophilia Z133. The x-axis is 
set at the limit of detection (20 CFU/peg). CFU: Colo y-forming units. E ch dat  point represent  a 
replicate, for a t tal of 12 replicates per condition. 
  
  
  
 
Control
NAC 1.6 mg/ml
NAC 8 mg/ml
NAC 16 mg/ml
COL 8 g/ml
COL 8 g/ml + NAC 1.6 mg/ml
COL 8 g/ml + NAC 8 mg/ml
COL 8 /ml + NAC 16 mg/ml
COL 32 g/ml
COL 32 g/ml + NAC 1.6 mg/ml
COL 32 g/ml + NAC 8 mg/ml
COL 32 g/ml + NAC 16 mg/ml
COL 128 g/ml
COL 128 g/ml + NAC 1.6 mg/ml
COL 128 g/ml + NAC 8 mg/ml
COL 128 g/ml + NAC 16 mg/ml
 
Figure 5. Antibiofilm activity of colistin/NAC combinations against S. maltophilia Z133. The x-axis is
set at the limit of detection (20 CFU/peg). CFU: Colony-forming units. Each data point represents a
replicate, for a total of 12 replicates per condition.
Antibiotics 2019, 8, 101 9 of 13
3. Discussion
Colistin/NAC combinations, at the high concentrations potentially achievable by topical
administration, have been recently found to exert a relevant synergistic activity against A. baumannii
grown in planktonic and biofilm phase [22]. In particular, NAC was demonstrated to revert the colistin
resistance phenotype in this pathogen and to significantly potentiate colistin antibiofilm activity [22].
Our study demonstrated that the antimicrobial and antibiofilm synergism of colistin/NAC
combinations is also exerted against S. maltophilia, an emerging global difficult-to-treat opportunistic
pathogen, with a relevant role in respiratory tract infections, especially in CF.
Inhaled colistin has been increasingly used since late 1980s, especially for the treatment of
individuals with CF, health care-associated pneumonia, and ventilator-associated pneumonia [15,25–27].
Very high colistin concentrations (up to 1137 µg/mL) have been reported in the epithelial lining
fluid (ELF) of critically ill patients, after aerosol delivery of 2 million IU (MIU) of colistin
methanesulfonate [19,20]. In addition, even higher ELF concentrations are expected to be achieved by
using colistin dry powder formulations, which have recently been approved [15,26,28].
Despite inhaled NAC has been used safely for decades as a mucus-dissolving treatment
in respiratory diseases associated to abundant and/or thick mucus production (e.g., CF, COPD,
bronchiectasis), the actual NAC concentrations achievable in the ELF after topical administration
have never been determined. Nonetheless, considering the multiple-dosage regimes of nebulized
administration (e.g., 1–10 mL of 200 mg/mL solution every 6–8 h), the higher performance of
last-generation nebulizers, and the possibility of direct instillation, topical NAC could reach the
ELF concentrations needed for exerting the antimicrobial and antibiofilm potentiation of colistin
activity [16,29]. In addition, NAC dry powder formulations have recently been implemented, with
the aim of potentiating the penetration through the respiratory mucus of inhaled antibiotics (i.e.,
clarithromycin and fluoroquinolones) [30,31].
Colistin has gained a renewed interest only in the last years as salvage therapy for the treatment
of infections caused by multidrug-resistant Gram-negative pathogens, and many aspects concerning
the molecular mechanisms of colistin bactericidal activity and acquired resistance remain still scarcely
known [32,33]. Apart from the well described primary mechanism of action (i.e., interaction with
lipid A of lipopolysaccharide followed by bacterial membranes derangement), alternative secondary
antibacterial mechanisms have been proposed, including inhibition of NDH-2 respiratory chain
enzymes (i.e., type II NADH-quinone oxidoreductases) located in the plasma membrane [33–35].
In support to the existence of alternative secondary mechanisms of colistin, plasma membrane
disruption and oxidative damage have been demonstrated to have a role in colistin bactericidal activity
against some Gram-positive bacteria, which lack the primary colistin molecular target (i.e., lipid A of
lipopolysaccharide) [36].
Similarly, no solid data are available on the molecular mechanisms accounting for the intrinsic
antimicrobial and antibiofilm activity of NAC, which most likely is multifactorial [16]. NAC has
been hypothesized to exert its intrinsic antimicrobial activity by competitive inhibition of cysteine
utilization, reaction of the NAC sulfhydryl group with bacterial proteins, and perturbation of the
intracellular redox equilibrium with potential indirect effects on cell metabolism and intracellular signal
transduction pathways [16]. The antibiofilm activity of NAC could be related either to perturbation of
microbial physiology (e.g., responsible for inhibition of biofilm formation and/or induction of biofilm
disruption), or to a direct destabilization of biofilm matrix architecture (e.g., by chelation of calcium
and magnesium or interaction with crucial components in the matrix) [16].
The reasons accounting for the antimicrobial and antibiofilm synergism of colistin/NAC
combinations are not easy to be hypothesized due to the relevant knowledge gaps on the mechanisms
of action of both compounds. In this perspective, understanding the mechanisms of such a synergism
would be relevant not only for optimization of clinical applications but also for drug discovery purposes
(e.g., new molecular targets for antibiotic drugs, new compounds able to potentiate colistin activity).
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Based on the in vitro evidence of potentiation of colistin antimicrobial and antibiofilm activity
by NAC, in vivo animal models to evaluate the potential clinical relevance of topical colistin/NAC
combinations are warranted.
4. Materials and Methods
4.1. Bacterial Strains Tested
A total of 18 S. maltophilia clinical isolates were investigated, including isolates from CF and
SXT-resistant strains (Table 1). The strains were the same as in a previous study, aimed at investigating
the antimicrobial and antibiofilm activity of NAC against S. maltophilia [17]. Colistin (Applichem,
Darmstadt, Germany) MICs were determined using the reference broth microdilution method [37].
For the purposes of this study, S. maltophilia strains were categorized as susceptible or resistant to
colistin based on clinical breakpoints available for P. aeruginosa (MIC <2 µg/mL, susceptible; MIC
>2 µg/mL resistant) [12,13].
4.2. Preparation of NAC-Containing Medium
NAC stock solutions (100 mg/mL) were prepared immediately before use. NAC powder
(Zambon, Bresso, Italy) was dissolved in sterile double-distilled water, pH was adjusted at 6.5–6.8
with NaOH, and the solution was filtered through a 0.22-µm membrane filter. All experiments were
performed in cation-adjusted Mueller-Hinton broth (CAMHB; Becton Dickinson, Milan, Italy), starting
from an appropriately concentrated medium in order to avoid broth dilution when testing high
NAC concentrations.
4.3. Checkerboard Assays
The potential synergism of colistin/NAC combinations was investigated by checkerboard assay
as described previously [38]. The ranges of colistin concentrations tested were 0.003–4 µg/mL and
0.25–256 µg/mL for colistin-susceptible and colistin-resistant strains, respectively. Considering the high
drug concentrations potentially achievable by topical administration, the range of NAC concentrations
tested was 0.5–32 mg/mL for all strains [16,19]. FICIs values were interpreted as follows: ≤0.5, synergy;
>0.5–≤1, partial synergism; >1–4.0, no interaction; >4.0, antagonism.
4.4. Time–Kill Assays of Colistin/NAC Combinations Against Planktonic Cultures
Time–Kill assays were performed according to CLSI guidelines [39], with three selected
S. maltophilia strains: Z131 (from bloodstream infection; resistant to SXT, ceftazidime and levofloxacin;
colistin MIC = 8 µg/mL), Z157 (from CF; colistin MIC = 8 µg/mL), and Z66 (from lower respiratory
tract infection; colistin MIC = 0.25 µg/mL) (Table 1). Two colistin concentrations (i.e., 2 and 8 µg/mL
for colistin-resistant strains; 0.25 and 0.5 µg/mL for colistin-susceptible strains) and three NAC
concentrations (i.e., 1.6, 3.2, and 8 mg/mL, corresponding to 0.1× MIC, 0.2× MIC, and 0.5× MIC,
respectively, for the selected strains) were tested alone and in combination. Viable cell counts were
performed at the beginning of the experiment and after 2, 4, 6, 8, 24, and 48 h of exposure (detection
limit, 100 CFU/mL). Data were obtained from at least two independent experiments, with two replicates
per condition per experiment.
4.5. In Vitro Biofilm Susceptibility Testing
The potential antibiofilm synergism of colistin/NAC combinations was investigated using the
Nunc-TSP lid system (Thermo Fisher Scientific, Waltham, MA, USA), as described previously [24].
Briefly, biofilms were grown for 24 h in CAMHB at 35 ◦C, static conditions. Preformed biofilms were
then exposed to three concentrations of colistin (i.e., 8, 32, and 128 µg/mL) and NAC (i.e., 1.6, 8. and
16 mg/mL), alone or in combination. After 24 h of exposure (i.e., 35 ◦C, static conditions), loosely
attached bacteria were removed by two 1-minute washes with 200 µL of phosphate-buffered saline (PBS)
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(Sigma Aldrich, Milan, Italy). Biofilms were then subjected to 30-minutes sonication (Elma Transsonic
T 460, Singen, Germany) in 200 µL of tryptic soy broth (TSB) (Oxoid, Milan, Italy) supplemented with
0.1% Tween 20 (Sigma Aldrich) (i.e., the recovery medium) to remove sessile cells. Mean viable cell
counts per peg (CFU/peg) were determined by plating 10 µL of appropriate dilutions of the recovery
medium onto tryptic soy agar (TSA) (Oxoid) plates and incubating for 24 h at 35 ◦C (detection limit,
20 CFU/peg). Colony count was also repeated after 48 h of incubation. Data were obtained in at least
two independent experiments, with at least six replicates per condition per experiment.
4.6. Statistical Analysis
Statistical analysis was performed using GraphPad Prism version 6.0 (San Diego, CA, USA).
D’Agostino-Pearson and Shapiro-Wilk normality tests were applied. Multiple comparison tests were
performed by Kruskal-Wallis test with Dunn’s correction.
5. Conclusions
In conclusion, we demonstrated a relevant in vitro antimicrobial and antibiofilm activity of
colistin/NAC combinations (at the high concentrations likely achievable by topical administration)
against S. maltophilia, an emerging global difficult-to-treat opportunistic pathogen, with an important
role also in CF.
Further studies are needed to understand the molecular bases of such a synergism and to evaluate
the potential clinical relevance of colistin/NAC topical formulations.
6. Patents
International patent application No. WO2018/154091.
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